A novel variant in the PDE4D gene is the cause of Acrodysostosis type 2 in a Lithuanian patient: a case report.


Journal

BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676

Informations de publication

Date de publication:
15 Apr 2021
Historique:
received: 08 05 2020
accepted: 07 04 2021
entrez: 16 4 2021
pubmed: 17 4 2021
medline: 18 11 2021
Statut: epublish

Résumé

Acrodysostosis is a rare hereditary disorder described as a primary bone dysplasia with or without hormonal resistance. Pathogenic variants in the PRKAR1A and PDE4D genes are known genetic causes of this condition. The latter gene variants are more frequently identified in patients with midfacial and nasal hypoplasia and neurological involvement. The aim of our study was to analyse and confirm a genetic cause of acrodysostosis in a male patient. We report on a 29-year-old Lithuanian man diagnosed with acrodysostosis type 2. The characteristic phenotype includes specific skeletal abnormalities, facial dysostosis, mild intellectual disability and metabolic syndrome. Using patient's DNA extracted from peripheral blood sample, the novel, likely pathogenic, heterozygous de novo variant NM_001104631.2:c.581G > C was identified in the gene PDE4D via Sanger sequencing. This variant causes amino acid change (NP_001098101.1:p.(Arg194Pro)) in the functionally relevant upstream conserved region 1 domain of PDE4D. This report further expands the knowledge of the consequences of missense variants in PDE4D that affect the upstream conserved region 1 regulatory domain and indicates that pathogenic variants of the gene PDE4D play an important role in the pathogenesis mechanism of acrodysostosis type 2 without significant hormonal resistance.

Sections du résumé

BACKGROUND BACKGROUND
Acrodysostosis is a rare hereditary disorder described as a primary bone dysplasia with or without hormonal resistance. Pathogenic variants in the PRKAR1A and PDE4D genes are known genetic causes of this condition. The latter gene variants are more frequently identified in patients with midfacial and nasal hypoplasia and neurological involvement. The aim of our study was to analyse and confirm a genetic cause of acrodysostosis in a male patient.
CASE PRESENTATION METHODS
We report on a 29-year-old Lithuanian man diagnosed with acrodysostosis type 2. The characteristic phenotype includes specific skeletal abnormalities, facial dysostosis, mild intellectual disability and metabolic syndrome. Using patient's DNA extracted from peripheral blood sample, the novel, likely pathogenic, heterozygous de novo variant NM_001104631.2:c.581G > C was identified in the gene PDE4D via Sanger sequencing. This variant causes amino acid change (NP_001098101.1:p.(Arg194Pro)) in the functionally relevant upstream conserved region 1 domain of PDE4D.
CONCLUSIONS CONCLUSIONS
This report further expands the knowledge of the consequences of missense variants in PDE4D that affect the upstream conserved region 1 regulatory domain and indicates that pathogenic variants of the gene PDE4D play an important role in the pathogenesis mechanism of acrodysostosis type 2 without significant hormonal resistance.

Identifiants

pubmed: 33858404
doi: 10.1186/s12902-021-00741-6
pii: 10.1186/s12902-021-00741-6
pmc: PMC8051037
doi:

Substances chimiques

Cyclic Nucleotide Phosphodiesterases, Type 4 EC 3.1.4.17
PDE4D protein, human EC 3.1.4.17

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

71

Subventions

Organisme : Lietuvos Mokslo Taryba
ID : S-MIP-17-19/LSS-150000-1179

Références

Eur J Hum Genet. 2018 Nov;26(11):1611-1622
pubmed: 30006632
J Clin Res Pediatr Endocrinol. 2017 Dec 15;9(4):360-365
pubmed: 28515031
Cell Signal. 2014 Nov;26(11):2446-59
pubmed: 25064455
J Med Genet. 2014 Jan;51(1):45-54
pubmed: 24203977
Am J Hum Genet. 2012 Apr 6;90(4):740-5
pubmed: 22464250
Hum Mutat. 2013 Jan;34(1):97-102
pubmed: 23033274
Prog Nucleic Acid Res Mol Biol. 2001;69:249-315
pubmed: 11550796
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Hum Mol Genet. 2017 Oct 15;26(20):3883-3894
pubmed: 29016851
J Biol Chem. 2003 Feb 21;278(8):5493-6
pubmed: 12493749
J Bone Miner Res. 2016 Jun;31(6):1215-24
pubmed: 26763073
Eur J Endocrinol. 2016 Dec;175(6):P1-P17
pubmed: 27401862
J Biol Chem. 2000 Apr 7;275(14):10349-58
pubmed: 10744723
Am J Hum Genet. 2012 Apr 6;90(4):746-51
pubmed: 22464252
J Clin Endocrinol Metab. 2012 Dec;97(12):E2328-38
pubmed: 23043190
Biochem J. 2003 Feb 15;370(Pt 1):1-18
pubmed: 12444918
Cell Signal. 2016 Jul;28(7):719-24
pubmed: 26562185
Am J Med Genet A. 2014 Oct;164A(10):2529-34
pubmed: 25044890

Auteurs

Gunda Petraitytė (G)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. gunda.petraityte@mf.vu.lt.

Kamilė Šiaurytė (K)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Violeta Mikštienė (V)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Loreta Cimbalistienė (L)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Dovilė Kriaučiūnienė (D)

Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Aušra Matulevičienė (A)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Algirdas Utkus (A)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Eglė Preikšaitienė (E)

Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH